BioLineRX Ltd.  

(Public, TLV:BLRX)   Watch this stock  
Find more results for BLRX
-13.80 (-3.10%)
Delayed:   12:22PM GMT+3
TLV data delayed by 20 mins - Disclaimer
Currency in ILA unless noted
Range 429.60 - 438.00
52 week 2.88 - 438.00
Open 438.00
Vol / Avg. 49,172.00/87,279.00
Mkt cap 243.18M*
P/E     -
Div/yield     -
EPS -0.85*
Shares 56.43M
Beta     -
Inst. own     -
Nov 23, 2016
Q3 2016 BioLine RX Ltd Earnings Release (Estimated) - 9:45AM GMT+2 - Add to calendar
Nov 7, 2016
BioLine RX Ltd at EBD Group BIO-Europe Add to calendar
Sep 22, 2016
BioLine RX Ltd to Host Investor Breakfast Meeting September 22, 2016 in New York
Sep 12, 2016
BioLine RX Ltd at Rodman & Renshaw Global Investment Conference
Aug 11, 2016
Q2 2016 BioLine RX Ltd Earnings Call
Aug 11, 2016
Q2 2016 BioLine RX Ltd Earnings Release
Jul 5, 2016
BioLine RX Ltd Annual Shareholders Meeting

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -31.67% -32.91%
Return on average equity -33.83% -36.27%
Employees 48 -
CDP Score - -


2 HaMa'ayan Street Modi'in Technology Park
MODIIN, 7177871
+972-8-6429100 (Phone)
+972-8-6429101 (Fax)

Website links


BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease. The Company also has 11 pre-clinical stage development products for various indications.

Officers and directors

Aharon Schwartz Chairman of the Board
Age: 74
Kinneret Savitsky Chief Executive Officer
Age: 49
Philip Adam Serlin Chief Executive Officer
Age: 56
Mali Zeevi Chief Financial Officer
Merril Gersten Chief Scientific Officer
Arnon Aharon Vice President-Medical Affairs
Moshe Phillip M.D. Vice President of Medical Affairs and Senior Clinical Advisor
Age: 59
David Malek Vice President - Business Development
Age: 35
Leah Klapper General Manager, BioLine Innovations Jerusalem
Age: 1
Michael J. Anghel Director
Age: 77